Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Eisuke Ueda"'
Autor:
Marion G. Peters, Yasuhito Tanaka, Won Seog Kim, Xiaonan Hong, Kensei Tobinai, Shigeru Kusumoto, Andrew D. Zelenetz, Hiroshi Kuriki, Eisuke Ueda, Jie Jin, Günter Fingerle-Rowson, Hanna Piper-Lepoutre, Luca Arcaini, Tina Nielsen, Yok-Lam Kwong, Gila Sellam
Publikováno v:
Blood. 133:137-146
Risk of hepatitis B virus (HBV) reactivation was assessed in B-cell non-Hodgkin lymphoma (NHL) patients with resolved HBV infection (hepatitis B surface antigen negative, hepatitis B core antibody positive) who received obinutuzumab- or rituximab-con
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cc09c5da0b3d9a1c4ae97a378347d711
https://doi.org/10.1182/blood-2018-04-848044
https://doi.org/10.1182/blood-2018-04-848044
Autor:
Nobuhiro Takeshima, Toru Sugiyama, Kosei Tajima, Mika Mizuno, Yoichi Aoki, Manabu Sakurai, Tadaaki Nishikawa, Eisuke Ueda
Publikováno v:
Japanese Journal of Clinical Oncology
According to the specified primary objective, a regimen of cisplatin, paclitaxel and bevacizumab was tolerable in Japanese patients and demonstrated encouraging activity in this small single-arm study.
Background Adding bevacizumab to chemothera
Background Adding bevacizumab to chemothera
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b15bcecb8b42ef05fcd36110e2727d06
https://tsukuba.repo.nii.ac.jp/records/40851
https://tsukuba.repo.nii.ac.jp/records/40851
Autor:
Tohru Murayama, Keichiro Mihara, Kiyohiko Hatake, Toshiki Uchida, Kensei Tobinai, Takaaki Chou, Norifumi Tsukamoto, Koji Izutsu, Ken Ohmachi, Tomohiro Kinoshita, Hiroshi Kuriki, Noriko Usui, Yoshitaka Kikukawa, Takayuki Ishikawa, Masafumi Taniwaki, Eisuke Ueda, Kyoya Kumagai, Kiyoshi Ando, Ilseung Choi, Ken Ohmine, Isao Yoshida, Fumihiro Ishida, Kohmei Kubo, Kunihiro Tsukasaki, Yuri Kamitsuji, Satoshi Ichikawa, Shinsuke Iida
Publikováno v:
International journal of hematology. 108(5)
GALLIUM is a global phase III study that demonstrated a statistically significant and clinically meaningful improvement in progression-free survival (PFS) with obinutuzumab plus chemotherapy (G-chemo) versus rituximab plus chemotherapy (R-chemo) in p
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b66556624cf384489c7ffcfd4c960af9
https://pubmed.ncbi.nlm.nih.gov/30027429
https://pubmed.ncbi.nlm.nih.gov/30027429
Autor:
Koji Kato, Kiyohiko Hatake, Kensei Tobinai, Hideki Tsujimura, Tomohiro Kinoshita, Koji Izutsu, Eisuke Ueda, Takayuki Ishikawa, Kiyoshi Ando, Hiroshi Kuriki, Takanori Teshima, Kyoya Kumagai, Kiyohiko Nakai
Publikováno v:
Blood. 128:5389-5389
Background Obinutuzumab (GA101) is a novel humanized, glycoengineered Type II anti-CD20 monoclonal antibody. It has greater direct cell death induction and antibody-dependent cell-mediated cytotoxicity and lower complement-dependent cytotoxicity than
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1244ef92ec4c7d50ad851da147d89625
https://doi.org/10.1182/blood.v128.22.5389.5389
https://doi.org/10.1182/blood.v128.22.5389.5389
Publikováno v:
SHINKU. 36:414-419
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ff33adcb1309820281cdbaa02fcc75d6
https://doi.org/10.3131/jvsj.36.414
https://doi.org/10.3131/jvsj.36.414
Autor:
Toru Sugiyama, Mika Mizuno, Yoichi Aoki, Manabu Sakurai, Tadaaki Nishikawa, Eisuke Ueda, Kosei Tajima, Nobuhiro Takeshima
Publikováno v:
Japanese Journal of Clinical Oncology; Jan2017, Vol. 47 Issue 1, p39-46, 8p
Publikováno v:
SHINKU. 22:111-114
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::42e87c7a51e84b4bd5c3a092f6aef1b9
https://doi.org/10.3131/jvsj.22.111
https://doi.org/10.3131/jvsj.22.111